Evidence map›Paper›PMID 34324734›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2021

Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro.

Juliana C Ferreira, Samar Fadl, Metehan Ilter, Hanife Pekel, Rachid Rezgui, Ozge Sensoy, Wael M Rabeh

Open access · bronzeAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Juliana C FerreiraScience Division, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
Samar FadlScience Division, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
Metehan IlterGraduate School of Engineering and Natural Sciences, Istanbul Medipol University, Istanbul, Turkey.
Hanife PekelDepartment of Pharmacy Services, Vocational School of Health Services, Istanbul Medipol University, Istanbul, Turkey.
Rachid RezguiCore Technology Platforms, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
Ozge SensoyRegenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, Turkey.
Wael M RabehScience Division, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
New York University Abu Dhabi · AEIstanbul Medipol University · TR

Funding

New York University Abu Dhabi COVID-19 Facilitator Research Fund (grant number: ADC05)
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19), one of the most challenging global pandemics of the modern era. Potential treatment strategies against COVID-19 are yet to be devised. It is crucial that antivirals that interfere with the SARS-CoV-2 life cycle be identified and developed. 3-Chymotrypsin-like protease (3CLpro) is an attractive antiviral drug target against SARS-CoV-2, and coronaviruses in general, because of its role in the processing of viral polyproteins. Inhibitors of 3CLpro activity are screened in enzyme assays before further development of the most promising leads. Dimethyl sulfoxide (DMSO) is a common additive used in such assays and enhances the solubility of assay components. However, it may also potentially affect the stability and efficiency of 3CLpro but, to date, this effect had not been analyzed in detail. Here, we investigated the effect of DMSO on 3CLpro-catalyzed reaction. While DMSO (5%-20%) decreased the optimum temperature of catalysis and thermodynamic stability of 3CLpro, it only marginally affected the kinetic stability of the enzyme. Increasing the DMSO concentration up to 20% improved the catalytic efficiency and peptide-binding affinity of 3CLpro. At such high DMSO concentration, the solubility and stability of peptide substrate were improved because of reduced aggregation. In conclusion, we recommend 20% DMSO as the minimum concentration to be used in screens of 3CLpro inhibitors as lead compounds for the development of antiviral drugs against COVID-19.

Indexed as

Computer SimulationCoronavirus 3C ProteasesCOVID-19Dimethyl SulfoxideGene Expression Regulation, EnzymologicGene Expression Regulation, ViralHumansMicrofluidic Analytical TechniquesPeptidesProtein StabilitySARS-CoV-2Coronavirus 3C ProteasesDimethyl SulfoxidePeptides3-chymotrypsin-like protease (3CLpro)COVID-19DMSOinitial velocitySARS-CoV-2thermodynamic stability

Identifiers

PMID34324734
PMCPMC8441638
OpenAlexW3183625084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.